Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
Status:
WITHDRAWN
Trial end date:
2022-05-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the administration of the CGRP-receptor antagonist erenumab is effective in decreasing pain and improving quality of life in patients with FMS by comparing the difference in pain scores in Fibromyalgia Impact Questionnaire, defense and veterans Pain Rating Scale and The American College of Rheumatology 2010 Preliminary Diagnostic Criteria for Fibromyalgia score over the study period.